Real-World Prognostic & Predictive Implications of EORTC & MRS Scores for Immunotherapy and Chemotherapy in Pleural Mesothelioma (PM)

被引：0
|
作者：
Wu, F. T. H. [1 ,2 ]
D'Amours, M. -F. [1 ]
Usman, F. [1 ]
Hussein, A. [1 ]
Bhang, E. [1 ]
Sarvestani, M. Kamali [1 ]
Lee, C. W. [2 ,3 ]
Ho, C. [1 ,2 ]
机构：
[1] BC Canc Vancouver Ctr, Vancouver, BC, Canada
[2] Univ British Columbia, Vancouver, BC, Canada
[3] BC Canc Surrey Ctr, Surrey, BC, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
pleural mesothelioma; prognostic; predictive;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4.14C.03
引用
收藏
页码：S409 / S409
页数：1
相关论文
共 50 条
  • [31] Histologic Subtype Informs Real-World Immune Checkpoint Inhibitor Uptake in Patients with Malignant Pleural Mesothelioma
    Kim, R.
    Mitra, N.
    Bagley, S. J.
    Marmarelis, M. E.
    Haas, A. R.
    Rendle, K. A.
    Vachani, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [32] Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
    Assie, Jean-Baptiste
    Crepin, Florian
    Grolleau, Emmanuel
    Canellas, Anthony
    Geier, Margaux
    Grebert-Manuardi, Aude
    Akkache, Nabila
    Renault, Aldo
    Hauss, Pierre-Alexandre
    Sabatini, Marielle
    Bonnefoy, Valentine
    Cortot, Alexis
    Wislez, Marie
    Gauvain, Clement
    Chouaid, Christos
    Scherpereel, Arnaud
    Monnet, Isabelle
    CANCERS, 2022, 14 (06)
  • [33] Nivolumab in Recurrent Malignant Pleural Mesothelioma: Real-World Data From Expanded Access Program In The Netherlands
    Belderbos, R.
    Cantini, L.
    Gooijer, C.
    Dumoulin, D.
    Cornelissen, R.
    Burgers, S.
    Baas, P.
    Aerts, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S123 - S123
  • [34] Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy
    Kerrigan, K.
    Chipman, J.
    Jo, Y. J.
    Haaland, B.
    Johnson, E.
    Puri, S.
    Varghese, T.
    Akerley, W.
    Patel, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S199 - S199
  • [35] Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting
    Shah, Rajiv
    Reck, Martin
    Grohe, Christian
    Christoph, Daniel Christian
    Buchmeier, Eva Lotte
    Saalfeld, Felix Carl
    Frost, Nikolaj
    Kopp, Hans-Georg
    Faehling, Martin
    Griesinger, Frank
    Roeper, Julia
    Hoffknecht, Petra
    Kuon, Jonas
    Luan, Jingting
    Chesi, Paolo
    Christopoulos, Petros
    Thomas, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Prognostic factors and clinical outcomes of malignant pleural mesothelioma in a real world-setting: An Asian cohort
    Wu, T-H.
    Lee, L. J-H.
    Yuan, C-T.
    Chen, T. W-W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients
    Karsten, Maria M.
    Roehle, Robert
    Albers, Sarah
    Pross, Therese
    Hage, Anna M.
    Weiler, Karoline
    Fischer, Felix
    Rose, Matthias
    Kuehn, Friedrich
    Blohmer, Jens-Uwe
    EUROPEAN JOURNAL OF CANCER, 2022, 163 : 128 - 139
  • [38] Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
    Kutuk, Tugce
    Appel, Haley
    Avendano, Maria Carolina
    Albrecht, Federico
    Kaywin, Paul
    Ramos, Suyen
    Suarez-Murias, Melanie E.
    Mehta, Minesh P.
    Kotecha, Rupesh
    CANCERS, 2022, 14 (08)
  • [39] Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
    Fujimoto, Nobukazu
    Akamatsu, Ayumi
    Honda, Chikara
    Aoki, Miki
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [40] Immunotherapy adverse events association with inflammation scores: A real-world data analysis from a Portuguese hospital
    Fernandes, C. L.
    Teixeira da Costa, M.
    Silva, D. J.
    Mesquita, A. A.
    Estevinho, F.
    Menezes Magalhaes, H. I.
    Salgado, M.
    Pinho, M. S.
    Sottomayor, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1129 - S1129
12345